BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Peitz U, Hackelsberger A, Malfertheiner P. A practical approach to patients with refractory Helicobacter pylori infection, or who are re-infected after standard therapy. Drugs. 1999;57:905-920. [PMID: 10400404 DOI: 10.2165/00003495-199957060-00006] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 2.1] [Reference Citation Analysis]
Number Citing Articles
1 Moya DA, Crissinger KD. Helicobacter Pylori Persistence in Children: Distinguishing Inadequate Treatment, Resistant Organisms, and Reinfection. Curr Gastroenterol Rep 2012;14:236-42. [DOI: 10.1007/s11894-012-0251-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
2 Fischbach L, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther. 2007;26:343-357. [PMID: 17635369 DOI: 10.1111/j.1365-2036.2007.03386.x] [Cited by in Crossref: 220] [Cited by in F6Publishing: 211] [Article Influence: 14.7] [Reference Citation Analysis]
3 Peitz U, Sulliga M, Wolle K, Leodolter A, Von Arnim U, Kahl S, Stolte M, Börsch G, Labenz J, Malfertheiner P. High rate of post-therapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two second-line therapies in a randomized study. Aliment Pharmacol Ther. 2002;16:315-324. [PMID: 11860415 DOI: 10.1046/j.1365-2036.2002.01173.x] [Cited by in Crossref: 73] [Cited by in F6Publishing: 71] [Article Influence: 3.7] [Reference Citation Analysis]
4 Nguyen TV, Bengtsson C, Nguyen GK, Yin L, Hoang TT, Phung DC, Sörberg M, Granström M. Age as risk factor for Helicobacter pylori recurrence in children in Vietnam. Helicobacter 2012;17:452-7. [PMID: 23066789 DOI: 10.1111/j.1523-5378.2012.00968.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
5 Kim SY, Hyun JJ, Jung SW, Koo JS, Yim HJ, Lee SW. Helicobacter pylori recurrence after first- and second-line eradication therapy in Korea: the problem of recrudescence or reinfection. Helicobacter. 2014;19:202-206. [PMID: 24612156 DOI: 10.1111/hel.12117] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
6 Gisbert JP, Luna M, Gomez B, Herrerias JM, Mones J, Castro-fernandez M, Sanchez-pobre P, Cosme A, Olivares D, Pajares JM. Recurrence of Helicobacter pylori infection after several eradication therapies: long-term follow-up of 1000 patients. Aliment Pharmacol Ther 2006;23:713-9. [DOI: 10.1111/j.1365-2036.2006.02827.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 2.1] [Reference Citation Analysis]
7 Gisbert JP. Second-line rescue therapy of helicobacter pylori infection. Therap Adv Gastroenterol. 2009;2:331-356. [PMID: 21180581 DOI: 10.1177/1756283x09347109] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
8 Ammon S, Treiber G, Kees F, Klotz U. Influence of age on the steady state disposition of drugs commonly used for the eradication of Helicobacter pylori. Aliment Pharmacol Ther 2000;14:759-66. [PMID: 10848660 DOI: 10.1046/j.1365-2036.2000.00756.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
9 Klotz U. Pharmacokinetic considerations in the eradication of Helicobacter pylori. Clin Pharmacokinet 2000;38:243-70. [PMID: 10749519 DOI: 10.2165/00003088-200038030-00004] [Cited by in Crossref: 76] [Cited by in F6Publishing: 62] [Article Influence: 3.5] [Reference Citation Analysis]
10 Mahachai V, Vilaichone RK, Pittayanon R, Rojborwonwitaya J, Leelakusolvong S, Maneerattanaporn M, Chotivitayatarakorn P, Treeprasertsuk S, Kositchaiwat C, Pisespongsa P, Mairiang P, Rani A, Leow A, Mya SM, Lee YC, Vannarath S, Rasachak B, Chakravuth O, Aung MM, Ang TL, Sollano JD, Trong Quach D, Sansak I, Wiwattanachang O, Harnsomburana P, Syam AF, Yamaoka Y, Fock KM, Goh KL, Sugano K, Graham D. Helicobacter pylori management in ASEAN: The Bangkok consensus report. J Gastroenterol Hepatol. 2018;33:37-56. [PMID: 28762251 DOI: 10.1111/jgh.13911] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 12.8] [Reference Citation Analysis]
11 Zendehdel N, Nasseri-Moghaddam S, Malekzadeh R, Massarrat S, Sotoudeh M, Siavoshi F. Helicobacter pylori reinfection rate 3 years after successful eradication. J Gastroenterol Hepatol. 2005;20:401-404. [PMID: 15740483 DOI: 10.1111/j.1440-1746.2005.03561.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.1] [Reference Citation Analysis]
12 Labenz J. Current role of acid suppressants in Helicobacter pylori eradication therapy. Best Pract Res Clin Gastroenterol 2001;15:413-31. [PMID: 11403536 DOI: 10.1053/bega.2001.0188] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 1.7] [Reference Citation Analysis]
13 Gisbert JP, Pérez-Aisa A, Castro-Fernández M, Barrio J, Rodrigo L, Cosme A, Gisbert JL, Marcos S, Moreno-Otero R. Helicobacter pylori first-line treatment and rescue option containing levofloxacin in patients allergic to penicillin. Dig Liver Dis. 2010;42:287-290. [PMID: 19632166 DOI: 10.1016/j.dld.2009.06.007] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 2.8] [Reference Citation Analysis]
14 Niv Y. H pylori recurrence after successful eradication. World J Gastroenterol 2008; 14(10): 1477-1478 [PMID: 18330934 DOI: 10.3748/wjg.14.1477] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 41] [Article Influence: 3.1] [Reference Citation Analysis]
15 Gisbert JP. Rescue Therapy for Helicobacter pylori Infection 2012. Gastroenterol Res Pract. 2012;2012:974594. [PMID: 22536225 DOI: 10.1155/2012/974594] [Cited by in Crossref: 19] [Cited by in F6Publishing: 28] [Article Influence: 1.9] [Reference Citation Analysis]
16 Qasim A, O'Morain CA. Review article: treatment of Helicobacter pylori infection and factors influencing eradication. Aliment Pharmacol Ther 2002;16 Suppl 1:24-30. [PMID: 11849124 DOI: 10.1046/j.1365-2036.2002.0160s1024.x] [Cited by in Crossref: 60] [Cited by in F6Publishing: 58] [Article Influence: 3.0] [Reference Citation Analysis]
17 Queiroz DM, Dani R, Silva LD, Santos A, Moreira LS, Rocha GA, Corrêa PR, Reis LF, Nogueira AM, Alvares Cabral MM, Esteves AM, Tanure J. Factors associated with treatment failure of Helicobacter pylori infection in a developing country. J Clin Gastroenterol 2002;35:315-20. [PMID: 12352294 DOI: 10.1097/00004836-200210000-00007] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 1.6] [Reference Citation Analysis]
18 Qasim A, O’morain CA, O’connor HJ. Helicobacter pylori eradication: role of individual therapy constituents and therapy duration. Fundamental & Clinical Pharmacology 2009;23:43-52. [DOI: 10.1111/j.1472-8206.2008.00635.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
19 Mamori S, Higashida A, Kawara F, Ohnishi K, Takeda A, Senda E, Ashida C, Yamada H. Age-dependent eradication of Helicobacter pylori in Japanese patients. World J Gastroenterol 2010; 16(33): 4176-4179 [PMID: 20806435 DOI: 10.3748/wjg.v16.i33.4176] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
20 Ungan M, Kulaçoǧlu H, Kayhan B. Cure rates obtained with five different Helicobacter pylori eradication protocols in patients with duodenal ulcer: a prospective, open-label randomized study in a primary care setting in Turkey. Current Therapeutic Research 2001;62:462-72. [DOI: 10.1016/s0011-393x(01)80057-6] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
21 de Argila CM, Boixeda D. Consideraciones prácticas para el diagnóstico de la infección por Helicobacter pylori. Medicina Clínica 2001;117:386-91. [DOI: 10.1016/s0025-7753(01)72122-7] [Cited by in Crossref: 7] [Article Influence: 0.3] [Reference Citation Analysis]
22 Nagahara A, Miwa H, Ohkura R, Yamada T, Sato K, Hojo M, Sato N. Strategy for retreatment of therapeutic failure of eradication of Helicobacter pylori infection. J Gastroenterol Hepatol. 2001;16:613-618. [PMID: 11422612 DOI: 10.1046/j.1440-1746.2001.02491.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 1.5] [Reference Citation Analysis]
23 Vester B, Douthwaite S. Macrolide resistance conferred by base substitutions in 23S rRNA. Antimicrob Agents Chemother. 2001;45:1-12. [PMID: 11120937 DOI: 10.1128/aac.45.1.1-12.2001] [Cited by in Crossref: 368] [Cited by in F6Publishing: 160] [Article Influence: 17.5] [Reference Citation Analysis]
24 Gisbert JP, Gisbert JL, Marcos S, Olivares D, Pajares JM. Helicobacter pylori first-line treatment and rescue options in patients allergic to penicillin. Aliment Pharmacol Ther 2005;22:1041-6. [DOI: 10.1111/j.1365-2036.2005.02687.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 2.2] [Reference Citation Analysis]
25 Kim MS, Kim N, Kim SE, Jo HJ, Shin CM, Lee SH, Park YS, Hwang JH, Kim JW, Jeong SH, Lee DH, Kim JM, Jung HC. Long-term follow-up Helicobacter pylori reinfection rate and its associated factors in Korea. Helicobacter. 2013;18:135-142. [PMID: 23066652 DOI: 10.1111/hel.12018] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 3.8] [Reference Citation Analysis]
26 Wedi B, Kapp A. Helicobacter pylori infection in skin diseases: a critical appraisal. Am J Clin Dermatol. 2002;3:273-282. [PMID: 12010072 DOI: 10.2165/00128071-200203040-00005] [Cited by in Crossref: 70] [Cited by in F6Publishing: 58] [Article Influence: 3.5] [Reference Citation Analysis]
27 Gisbert JP, Pajares JM. Review article: Helicobacter pylori “rescue” regimen when proton pump inhibitor-based triple therapies fail. Aliment Pharmacol Ther. 2002;16:1047-1057. [PMID: 12030945 DOI: 10.1046/j.1365-2036.2002.01276.x] [Cited by in Crossref: 166] [Cited by in F6Publishing: 152] [Article Influence: 8.3] [Reference Citation Analysis]
28 Riquelme A, Soza A, Pedreros C, Bustamante A, Valenzuela F, Otarola F, Abbott E, Arellano M, Medina B, Pattillo A, Greig D, Arrese M, Rollan A. Optimal length of triple therapy for H pylori eradication in a population with high prevalence of infection in Chile. World J Gastroenterol 2007; 13(21): 2967-2972 [PMID: 17589948 DOI: 10.3748/wjg.v13.i21.2967] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
29 Isakov V, Domareva I, Koudryavtseva L, Maev I, Ganskaya Z. Furazolidone-based triple 'rescue therapy' vs. quadruple 'rescue therapy' for the eradication of Helicobacter pylori resistant to metronidazole. Aliment Pharmacol Ther. 2002;16:1277-1282. [PMID: 12144577 DOI: 10.1046/j.1365-2036.2002.01299.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 2.1] [Reference Citation Analysis]
30 Niv Y, Hazazi R, Waked A, Lederfein T, Achiel K. Helicobacter pylori recurrence and infection rate in Israeli adults. Dig Dis Sci 2008;53:1211-4. [PMID: 17939051 DOI: 10.1007/s10620-007-0016-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
31 Corral JE, Mera R, Dye CW, Morgan DR. Helicobacter pylori recurrence after eradication in Latin America: Implications for gastric cancer prevention. World J Gastrointest Oncol 2017; 9(4): 184-193 [PMID: 28451066 DOI: 10.4251/wjgo.v9.i4.184] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
32 Fakheri H, Bakhshi Z, Bari Z, Alhooei S. Effects of Clarithromycin-Containing Quadruple Therapy on Helicobacter Pylori Eradication after Nitroimidazole-Containing Quadruple Therapy Failure. Middle East J Dig Dis 2016;8:51-6. [PMID: 26933482 DOI: 10.15171/mejdd.2016.07] [Cited by in Crossref: 4] [Article Influence: 0.7] [Reference Citation Analysis]
33 Collins J, Ali-ibrahim A, Smoot DT. Antibiotic Therapy for Helicobacter pylori. Medical Clinics of North America 2006;90:1125-40. [DOI: 10.1016/j.mcna.2006.07.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
34 Niv Y, Hazazi R. Helicobacter pylori recurrence in developed and developing countries: Meta-analysis of 13C-urea breath test follow-up after eradication. Helicobacter. 2008;13:56-61. [PMID: 18205667 DOI: 10.1111/j.1523-5378.2008.00571.x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 48] [Article Influence: 3.6] [Reference Citation Analysis]
35 Hawkyard CV, Koerner RJ. The use of erythromycin as a gastrointestinal prokinetic agent in adult critical care: benefits versus risks. Journal of Antimicrobial Chemotherapy 2007;59:347-58. [DOI: 10.1093/jac/dkl537] [Cited by in Crossref: 61] [Cited by in F6Publishing: 48] [Article Influence: 4.1] [Reference Citation Analysis]
36 Gisbert JP. The recurrence of Helicobacter pylori infection: incidence and variables influencing it. A critical review. Am J Gastroenterol. 2005;100:2083-2099. [PMID: 16128956 DOI: 10.1111/j.1572-0241.2005.50043.x] [Cited by in Crossref: 81] [Cited by in F6Publishing: 75] [Article Influence: 4.8] [Reference Citation Analysis]
37 Vicente R, Sicilia B, Gallego S, Revillo MJ, Ducóns J, Gomollón F. [Helicobacter pylori eradication in patients with peptic ulcer after two treatment failures: a prospective culture-guided study]. Gastroenterol Hepatol. 2002;25:438-442. [PMID: 12139836 DOI: 10.1016/s0210-5705(02)70283-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
38 Sicilia B, Sierra E, Lago A, Villar M, Gomollón F. Alto índice de erradicación de Helicobacter pylori en pacientes con úlcera duodenal tras fracaso de un tratamiento previo. Medicina Clínica 2000;115:641-3. [DOI: 10.1016/s0025-7753(00)71649-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
39 Tsai T, Chen Y. Pharmacokinetics of metronidazole in rat blood, brain and bile studied by microdialysis coupled to microbore liquid chromatography. Journal of Chromatography A 2003;987:277-82. [DOI: 10.1016/s0021-9673(02)01454-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
40 Leodolter A, Wolle K, von Arnim U, Kahl S, Treiber G, Ebert MP, Peitz U, Malfertheiner P. Breath and string test: A diagnostic package for the identification of treatment failure and antibiotic resistance of Helicobacter pylori without the necessity of upper gastrointestinal endoscopy. World J Gastroenterol 2005; 11(4): 584-586 [PMID: 15641151 DOI: 10.3748/wjg.v11.i4.584] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
41 Gumurdulu Y, Serin E, Özer B, Kayaselcuk F, Ozsahin K, Cosar AM, Gursoy M, Gur G, Yilmaz U, Boyacioglu S. Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey. World J Gastroenterol 2004; 10(5): 668-671 [PMID: 14991935 DOI: 10.3748/wjg.v10.i5.668] [Cited by in CrossRef: 68] [Cited by in F6Publishing: 75] [Article Influence: 3.8] [Reference Citation Analysis]
42 Kim MS, Kim N, Kim SE, Jo HJ, Shin CM, Park YS, Lee DH. Long-term follow up Helicobacter Pylori reinfection rate after second-line treatment: bismuth-containing quadruple therapy versus moxifloxacin-based triple therapy. BMC Gastroenterol. 2013;13:138. [PMID: 24050512 DOI: 10.1186/1471-230x-13-138] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
43 Gisbert JP, Pajares JM. Helicobacter pylori "rescue" therapy after failure of two eradication treatments. Helicobacter. 2005;10:363-372. [PMID: 16181345 DOI: 10.1111/j.1523-5378.2005.00324.x] [Cited by in Crossref: 78] [Cited by in F6Publishing: 70] [Article Influence: 4.6] [Reference Citation Analysis]
44 Gisbert JP. “Rescue” regimens after Helicobacter pylori treatment failure. World J Gastroenterol 2008; 14(35): 5385-5402 [PMID: 18803350 DOI: 10.3748/wjg.14.5385] [Cited by in CrossRef: 79] [Cited by in F6Publishing: 77] [Article Influence: 5.6] [Reference Citation Analysis]
45 Xie Y, Song C, Cheng H, Xu C, Zhang Z, Wang J, Huo L, Du Q, Xu J, Chen Y, Zhang X, Zhang G, Yang G, Zuo X, Guo T, Lu Y, Wang F, Wang X, Zhuang K, Chen S, Liu W, Lu N; Chinese Society of Gastroenterology, Chinese Study Group on Helicobacter pylori and Peptic Ulcer. Long-term follow-up of Helicobacter pylori reinfection and its risk factors after initial eradication: a large-scale multicentre, prospective open cohort, observational study. Emerg Microbes Infect 2020;9:548-57. [PMID: 32160805 DOI: 10.1080/22221751.2020.1737579] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]